IDXX icon

Idexx Laboratories

459.78 USD
-0.78
0.17%
At close Feb 7, 4:00 PM EST
After hours
459.78
+0.00
0.00%
1 day
-0.17%
5 days
-1.12%
1 month
7.61%
3 months
6.18%
6 months
-1.56%
Year to date
12.46%
1 year
-19.66%
5 years
65.15%
10 years
501.49%
 

About: Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.

Employees: 11,000

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

20% more first-time investments, than exits

New positions opened: 103 | Existing positions closed: 86

0% more funds holding

Funds holding: 1,092 [Q2] → 1,096 (+4) [Q3]

2% less capital invested

Capital invested by funds: $37.4B [Q2] → $36.5B (-$835M) [Q3]

4.21% less ownership

Funds ownership: 92.88% [Q2] → 88.67% (-4.21%) [Q3]

14% less funds holding in top 10

Funds holding in top 10: 14 [Q2] → 12 (-2) [Q3]

17% less repeat investments, than reductions

Existing positions increased: 352 | Existing positions reduced: 425

46% less call options, than puts

Call options by funds: $95M | Put options by funds: $176M

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$500
9%
upside
Avg. target
$526
14%
upside
High target
$550
20%
upside

4 analyst ratings

positive
75%
neutral
25%
negative
0%
Barclays
Balaji Prasad
38% 1-year accuracy
15 / 40 met price target
13%upside
$520
Overweight
Maintained
4 Feb 2025
B of A Securities
Michael Ryskin
75% 1-year accuracy
3 / 4 met price target
16%upside
$535
Neutral
Maintained
4 Feb 2025
Morgan Stanley
Erin Wright
64% 1-year accuracy
18 / 28 met price target
20%upside
$550
Overweight
Maintained
29 Jan 2025
Leerink Partners
Daniel Clark
50% 1-year accuracy
1 / 2 met price target
9%upside
$500
Outperform
Initiated
2 Dec 2024

Financial journalist opinion

Based on 16 articles about IDXX published over the past 30 days

Positive
The Motley Fool
12 hours ago
Why Idexx Labs Stock Rocketed Higher This Week
Shares of leading pet healthcare diagnostics provider Idexx Laboratories (IDXX -1.70%) were up by 9% this week as of 4 p.m. ET Thursday, according to data provided by S&P Global Market Intelligence.
Why Idexx Labs Stock Rocketed Higher This Week
Positive
Seeking Alpha
1 day ago
IDEXX Laboratories: I See Pet Healthcare As An Interesting Market For The Future
IDEXX Laboratories is poised for growth in the pet healthcare market, driven by an aging pet population and strong pet-owner bonds. IDEXX's comprehensive ecosystem, including AI-driven diagnostics and software, enhances veterinary practices and pet health monitoring, creating significant value for pet owners. IDEXX's strong balance sheet, shareholder-friendly capital allocation, and high ROIC of 32% indicate robust financial health and competitive advantage.
IDEXX Laboratories: I See Pet Healthcare As An Interesting Market For The Future
Positive
Barrons
4 days ago
Idexx Stock, AbbVie, and Molina Buck Downward Tariff Trend. These Are Today's Top S&P 500 Performers.
Idexx Laboratories, AbbVie, and Molina Healthcare trade higher on a down day for Wall Street.
Idexx Stock, AbbVie, and Molina Buck Downward Tariff Trend. These Are Today's Top S&P 500 Performers.
Neutral
Seeking Alpha
4 days ago
IDEXX Laboratories, Inc. (IDXX) Q4 2024 Earnings Call Transcript
IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q4 2024 Earnings Conference Call February 3, 2025 8:30 AM ET Company Participants Brian McKeon - Chief Financial Officer Andrew Emerson - Senior Vice President, Corporate & Companion Animal Group Finance Jay Mazelsky - President & Chief Executive Officer Conference Call Participants Erin Wright - Morgan Stanley Chris Schott - JPMorgan Michael Ryskin - Bank of America Jon Block - Stifel Daniel Clark - Leerink Partners Navann Ty - BNP Paribas Exane Operator Good morning, and welcome to the IDEXX Laboratories' Fourth Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being recorded.
IDEXX Laboratories, Inc. (IDXX) Q4 2024 Earnings Call Transcript
Positive
Investopedia
4 days ago
IDEXX Laboratories Stock Jumps on Testing Products Demand, Higher Prices
Shares of IDEXX Laboratories (IDXX) surged 10% to lead S&P 500 gainers Monday after the provider of veterinary healthcare products and services reported better-than-anticipated results on demand for its animal testing products and higher prices.
IDEXX Laboratories Stock Jumps on Testing Products Demand, Higher Prices
Positive
Zacks Investment Research
4 days ago
Idexx (IDXX) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Idexx (IDXX) Reports Q4 Earnings: What Key Metrics Have to Say
Positive
Investors Business Daily
4 days ago
Idexx Laboratories Barks Up A Beat, And Shares Jump To A Four-Month High
Idexx Laboratories handily beat Wall Street's fourth-quarter expectations Monday, and Idexx stock gapped up to a four-month high. The post Idexx Laboratories Barks Up A Beat, And Shares Jump To A Four-Month High appeared first on Investor's Business Daily.
Idexx Laboratories Barks Up A Beat, And Shares Jump To A Four-Month High
Positive
Benzinga
4 days ago
Why Is Pet Health Company IDEXX Laboratories Stock Trading Higher On Monday?
IDEXX Laboratories Inc IDXX reported fourth-quarter adjusted EPS of $2.53, up 10% year-over-year, beating the consensus of $2.40.
Why Is Pet Health Company IDEXX Laboratories Stock Trading Higher On Monday?
Positive
The Motley Fool
4 days ago
Idexx: Q4 EPS, Revenue Beat Forecast
Veterinary diagnostics specialist Idexx Laboratories (IDXX -0.46%) reported fourth-quarter earnings on Monday, Feb. 3, that topped analysts' consensus top- and bottom-line estimates. Revenue for the quarter came in at $954 million against the expected $935 million.
Idexx: Q4 EPS, Revenue Beat Forecast
Positive
Zacks Investment Research
4 days ago
Idexx Laboratories (IDXX) Q4 Earnings and Revenues Beat Estimates
Idexx Laboratories (IDXX) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.40 per share. This compares to earnings of $2.32 per share a year ago.
Idexx Laboratories (IDXX) Q4 Earnings and Revenues Beat Estimates
Charts implemented using Lightweight Charts™